A genomic biomarker that identifies human bone marrow-derived mesenchymal stem cells with high scalability.
Stem Cells
; 38(9): 1124-1136, 2020 09.
Article
de En
| MEDLINE
| ID: mdl-32510174
ABSTRACT
Although the application of human mesenchymal stem cells (hMSCs) to repair damaged or diseased tissues has proven relatively effective, both the donor-to-donor variability in ex vivo expansion rates and the maintenance of stemness remain a bottleneck to widespread translation. Previous work from this laboratory stratified donors into those yielding hMSCs with high- or low-growth capacity; global transcriptomic analysis revealed that high-growth-capacity hMSCs were characterized by a loss of the gene encoding glutathione S-transferase theta 1 (GSTT1). These GSTT1-null hMSCs demonstrated increased proliferative rates, clonogenic potential, and longer telomeres compared with low-growth capacity hMSCs that were GSTT1-positive. Thus, this study identifies GSTT1 as a novel genomic DNA biomarker for hMSC scalability.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Cellules de la moelle osseuse
/
Marqueurs biologiques
/
Génome humain
/
Cellules souches mésenchymateuses
Limites:
Humans
Langue:
En
Journal:
Stem Cells
Année:
2020
Type de document:
Article
Pays d'affiliation:
Singapour